Abstract: The present invention relates to a method for treatment of sepsis in a subject comprising administering a pharmaceutical composition comprising an effective amount of allogeneic Natural Killer cells to said subject, and to methods for predicting a subject's susceptibility to such method of treatment.

Abstract: The present invention relates to population of T cells with reduced expression of SIGLEC15, wherein the T cells are derived from sentinel lymph nodes in a subject having a cancer. The invention also relates to methods for obtaining such T cells, as well as to their use in therapy and pharmaceutical compositions comprising such T cells.

Abstract: A testing system is provided that includes a plurality of valves and a plurality of pumps. At least one of the pumps is coupled to at least one of the valves. A plurality of sensor arrays are coupled to at least one of the pumps or at least one of the valves for detecting at least one element. Each of the sensor arrays includes at least one serial connected sensor or parallel connected sensor.

Abstract: A testing system is provided that includes a plurality of valves and a plurality of pumps. At least one of the pumps is coupled to at least one of the valves. A plurality of sensor arrays are coupled to at least one of the pumps or at least one of the valves for detecting at least one element. Each of the sensor arrays includes at least one serial connected sensor or parallel connected sensor.

Abstract: A system for analyzing a gas mixture is provided. The system includes an enclosure inlet. A moisture trap assembly is coupled to the enclosure inlet. The moisture trap assembly removes excess moisture from a sample at the enclosure inlet. A testing section is coupled to the moisture trap assembly for detecting one or more compounds from the sample.

Abstract: The present invention relates to polymorphs of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (X842), more specifically forms A and B of X842. The invention also relates to a process for the preparation of these polymorphs, to pharmaceutical compositions comprising such polymorphs, and to methods for treating or preventing a gastrointestinal inflammatory disease or a gastric acid related disease, comprising administering a pharmaceutical composition comprising such polymorphs.

Abstract: A volatile organic compound (VOC) testing system is provided that includes a plurality of valves, and a plurality of pumps. At least one of the pumps is coupled to at least one of the valves. A plurality of sensors are coupled to the pumps and at least one of the valves. The sensors detect one or more volatile organic compounds.